SYSTEM BIOSCIENCES, LLC (SBI)

Biotech · Acquired

Engineered exosomes loaded with CRISPR/Cas9 machinery to deliver genome editing payloads targeting integrated HIV DNA in latently-infected cells

Grants
$160K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · This proposal is to develop engineered exosome CRISPR/saCas9 cargo to target HIV genomes and program exosome delivery to latently-infected cell types for HIV eradication.$160,354
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3158UNDERDOG PHARMACEUTICALS, INC.——
3159GENEXGEN INC——
3160Basis——
3161SYSTEM BIOSCIENCES, LLC (SBI)——
3162PACDNA LLC——
3163ANTEL BIOSYSTEMS, INC——
3164TORRALVA MEDICAL THERAPUETICS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.